Cryoport Inc Financials
This page shows Cryoport Inc (CYRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
In FY2025, reported profit hid a still cash-consuming operating model as liquidity improved outside the core business.
FY2025’s net profit of$78.3M and44.4% margin did not mark a full operating turnaround. Core operations were still negative, with EBITDA at-$9.1M and operating cash flow at-$8.6M , so the year’s earnings strength came from outside the recurring business engine and did not yet convert into cash.
Gross margin stayed near
Cash reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cryoport Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cryoport Inc scores 1.06, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($807.9M) relative to total liabilities ($262.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cryoport Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cryoport Inc generates $-0.11 in operating cash flow (-$8.6M OCF vs $78.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cryoport Inc earns $-15.6 in operating income for every $1 of interest expense (-$36.8M vs $2.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Cryoport Inc generated $176.2M in revenue in fiscal year 2025. This represents an increase of 12.4% from the prior year.
Cryoport Inc's EBITDA was -$9.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 90.0% from the prior year.
Cryoport Inc reported $78.3M in net income in fiscal year 2025. This represents an increase of 168.2% from the prior year.
Cryoport Inc earned $1.40 per diluted share (EPS) in fiscal year 2025. This represents an increase of 156.2% from the prior year.
Cash & Balance Sheet
Cryoport Inc generated -$25.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 25.5% from the prior year.
Cryoport Inc held $250.5M in cash against $0 in long-term debt as of fiscal year 2025.
Cryoport Inc had 50M shares outstanding in fiscal year 2025. This represents a decrease of 0.1% from the prior year.
Margins & Returns
Cryoport Inc's gross margin was 47.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the prior year.
Cryoport Inc's operating margin was -20.9% in fiscal year 2025, reflecting core business profitability. This is up 56.7 percentage points from the prior year.
Cryoport Inc's net profit margin was 44.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 117.6 percentage points from the prior year.
Cryoport Inc's ROE was 15.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 44.1 percentage points from the prior year.
Capital Allocation
Cryoport Inc invested $17.0M in research and development in fiscal year 2025. This represents a decrease of 3.8% from the prior year.
Cryoport Inc spent $10.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Cryoport Inc invested $16.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 4.7% from the prior year.
CYRX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.8M+5.2% | $45.5M+2.8% | $44.2M-2.7% | $45.5M+10.8% | $41.0M-1.0% | $41.5M+8.2% | $38.3M-3.5% | $39.7M |
| Cost of Revenue | $25.9M+9.0% | $23.7M+3.6% | $22.9M-4.9% | $24.1M+7.5% | $22.4M+2.0% | $22.0M+5.2% | $20.9M-5.3% | $22.0M |
| Gross Profit | $21.9M+0.9% | $21.7M+1.8% | $21.3M-0.2% | $21.4M+14.7% | $18.6M-4.4% | $19.5M+11.8% | $17.4M-1.3% | $17.7M |
| R&D Expenses | $3.9M-12.5% | $4.5M-1.3% | $4.5M+9.8% | $4.1M+4.7% | $3.9M-5.3% | $4.2M0.0% | $4.2M-10.5% | $4.6M |
| SG&A Expenses | $27.6M+1.3% | $27.3M+2.0% | $26.7M-0.6% | $26.9M+22.9% | $21.9M-22.0% | $28.1M+5.3% | $26.7M-2.1% | $27.2M |
| Operating Income | -$9.6M+4.2% | -$10.0M-1.0% | -$9.9M-2.9% | -$9.6M-34.1% | -$7.2M+43.6% | -$12.7M+4.8% | -$13.4M+82.8% | -$78.0M |
| Interest Expense | $432K-31.9% | $634K+20.5% | $526K-14.9% | $618K+6.0% | $583K+13.0% | $516K-41.5% | $882K-28.9% | $1.2M |
| Income Tax | $108K-90.4% | $1.1M+582.4% | $165K-39.8% | $274K+17.1% | $234K+274.6% | -$134K-142.4% | $316K+378.8% | $66K |
| Net Income | -$10.5M-32.5% | -$8.0M-14.6% | -$6.9M-106.6% | $105.2M+977.9% | -$12.0M+35.9% | -$18.7M-2420.6% | $805K+101.0% | -$78.0M |
| EPS (Diluted) | $-0.25 | N/A | $-0.18-108.8% | $2.05+832.1% | $-0.28 | N/A | $-0.02+98.8% | $-1.62 |
CYRX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $763.6M-0.2% | $765.0M-1.2% | $774.3M+0.1% | $773.9M+10.6% | $699.8M-0.5% | $703.5M+0.2% | $701.8M-17.7% | $852.3M |
| Current Assets | $470.5M-1.2% | $476.2M-1.8% | $484.8M-0.9% | $489.5M+19.0% | $411.3M+20.4% | $341.6M-2.5% | $350.3M-30.2% | $502.0M |
| Cash & Equivalents | $272.9M+8.9% | $250.5M-2.1% | $255.8M+5.1% | $243.4M+574.2% | $36.1M+5.8% | $34.1M+8.8% | $31.4M-8.2% | $34.2M |
| Inventory | $21.8M-6.2% | $23.2M-0.6% | $23.3M+1.3% | $23.0M-1.3% | $23.3M+8.7% | $21.5M-8.8% | $23.6M-0.2% | $23.6M |
| Accounts Receivable | $39.0M+16.9% | $33.4M-4.5% | $34.9M+4.5% | $33.4M+17.8% | $28.4M+12.1% | $25.3M-41.8% | $43.5M+8.2% | $40.2M |
| Goodwill | $22.1M-1.2% | $22.4M0.0% | $22.4M+19.8% | $18.7M-10.7% | $21.0M+1.9% | $20.6M-61.9% | $54.1M+3.2% | $52.4M |
| Total Liabilities | $268.6M+2.4% | $262.4M+0.5% | $261.1M+1.0% | $258.5M-14.1% | $301.0M-0.2% | $301.6M+6.5% | $283.2M-37.4% | $452.2M |
| Current Liabilities | $224.9M+2.7% | $219.0M+612.3% | $30.7M+2.0% | $30.1M-59.3% | $74.0M+14.7% | $64.6M+5.1% | $61.4M+2.6% | $59.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $495.0M-1.5% | $502.6M-2.1% | $513.3M-1.1% | $519.1M+30.2% | $398.8M-0.8% | $401.9M-4.0% | $418.6M+4.6% | $400.1M |
| Retained Earnings | -$699.4M-1.5% | -$688.9M-2.0% | -$675.2M-1.0% | -$668.2M+13.1% | -$769.2M-1.6% | -$757.2M-2.5% | -$738.5M+0.1% | -$739.3M |
CYRX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.7M+306.4% | $919K-58.0% | $2.2M+129.8% | -$7.3M-69.2% | -$4.3M+20.8% | -$5.5M-1326.0% | $447K+105.6% | -$8.0M |
| Capital Expenditures | $10.0M+82.6% | $5.5M+58.3% | $3.5M-20.6% | $4.4M+37.3% | $3.2M-39.3% | $5.2M+23.1% | $4.2M+11.8% | $3.8M |
| Free Cash Flow | -$6.2M-37.3% | -$4.5M-259.5% | -$1.3M+89.2% | -$11.7M-55.7% | -$7.5M+29.8% | -$10.7M-182.1% | -$3.8M+67.9% | -$11.8M |
| Investing Cash Flow | $18.7M+33325.0% | $56K-99.6% | $14.3M-93.8% | $230.0M+3784.5% | $5.9M+70.2% | $3.5M-97.7% | $153.6M+1052.8% | $13.3M |
| Financing Cash Flow | $85K+103.9% | -$2.2M+24.9% | -$2.9M+81.9% | -$15.9M-8293.7% | -$189K-109.4% | $2.0M+101.3% | -$155.3M-1671.9% | -$8.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $2.0M-46.4% | $3.7M | N/A | N/A | N/A | N/A | N/A |
CYRX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9%-1.9pp | 47.8%-0.4pp | 48.2%+1.2pp | 47.0%+1.6pp | 45.4%-1.6pp | 47.0%+1.5pp | 45.5%+1.0pp | 44.5% |
| Operating Margin | -20.1%+2.0pp | -22.1%+0.4pp | -22.4%-1.2pp | -21.2%-3.7pp | -17.5%+13.2pp | -30.8%+4.2pp | -34.9%+161.6pp | -196.5% |
| Net Margin | -22.1%-4.6pp | -17.5%-1.8pp | -15.7%-247.1pp | 231.4%+260.6pp | -29.2%+15.9pp | -45.1%-47.2pp | 2.1%+198.5pp | -196.4% |
| Return on Equity | -2.1%-0.5pp | -1.6%-0.2pp | -1.4%-21.6pp | 20.3%+23.3pp | -3.0%+1.6pp | -4.6%-4.8pp | 0.2%+19.7pp | -19.5% |
| Return on Assets | -1.4%-0.3pp | -1.0%-0.1pp | -0.9%-14.5pp | 13.6%+15.3pp | -1.7%+0.9pp | -2.7%-2.8pp | 0.1%+9.3pp | -9.2% |
| Current Ratio | 2.09-0.1 | 2.17-13.6 | 15.77-0.5 | 16.24+10.7 | 5.56+0.3 | 5.29-0.4 | 5.70-2.7 | 8.38 |
| Debt-to-Equity | 0.54+0.0 | 0.52+0.0 | 0.51+0.0 | 0.50-0.3 | 0.750.0 | 0.75+0.1 | 0.68-0.5 | 1.13 |
| FCF Margin | -13.1%-3.1pp | -10.0%-7.1pp | -2.9%+22.9pp | -25.7%-7.4pp | -18.3%+7.5pp | -25.8%-15.9pp | -9.9%+19.8pp | -29.8% |
Similar Companies
Frequently Asked Questions
What is Cryoport Inc's annual revenue?
Cryoport Inc (CYRX) reported $176.2M in total revenue for fiscal year 2025. This represents a 12.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cryoport Inc's revenue growing?
Cryoport Inc (CYRX) revenue grew by 12.4% year-over-year, from $156.8M to $176.2M in fiscal year 2025.
Is Cryoport Inc profitable?
Yes, Cryoport Inc (CYRX) reported a net income of $78.3M in fiscal year 2025, with a net profit margin of 44.4%.
What is Cryoport Inc's EBITDA?
Cryoport Inc (CYRX) had EBITDA of -$9.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cryoport Inc's gross margin?
Cryoport Inc (CYRX) had a gross margin of 47.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cryoport Inc's operating margin?
Cryoport Inc (CYRX) had an operating margin of -20.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cryoport Inc's net profit margin?
Cryoport Inc (CYRX) had a net profit margin of 44.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cryoport Inc's return on equity (ROE)?
Cryoport Inc (CYRX) has a return on equity of 15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cryoport Inc's free cash flow?
Cryoport Inc (CYRX) generated -$25.0M in free cash flow during fiscal year 2025. This represents a 25.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cryoport Inc's operating cash flow?
Cryoport Inc (CYRX) generated -$8.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cryoport Inc's total assets?
Cryoport Inc (CYRX) had $765.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cryoport Inc's capital expenditures?
Cryoport Inc (CYRX) invested $16.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cryoport Inc spend on research and development?
Cryoport Inc (CYRX) invested $17.0M in research and development during fiscal year 2025.
What is Cryoport Inc's current ratio?
Cryoport Inc (CYRX) had a current ratio of 2.17 as of fiscal year 2025, which is generally considered healthy.
What is Cryoport Inc's debt-to-equity ratio?
Cryoport Inc (CYRX) had a debt-to-equity ratio of 0.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cryoport Inc's return on assets (ROA)?
Cryoport Inc (CYRX) had a return on assets of 10.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cryoport Inc's cash runway?
Based on fiscal year 2025 data, Cryoport Inc (CYRX) had $250.5M in cash against an annual operating cash burn of $8.6M. This gives an estimated cash runway of approximately 350 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cryoport Inc's Altman Z-Score?
Cryoport Inc (CYRX) has an Altman Z-Score of 1.06, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cryoport Inc's Piotroski F-Score?
Cryoport Inc (CYRX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cryoport Inc's earnings high quality?
Cryoport Inc (CYRX) has an earnings quality ratio of -0.11x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cryoport Inc cover its interest payments?
Cryoport Inc (CYRX) has an interest coverage ratio of -15.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cryoport Inc?
Cryoport Inc (CYRX) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.